van Rhee, F., Szymonifka, J., Anaissie, E., Nair, B., Waheed, S., Alsayed, Y., . . . Barlogie, B. (2010). Total Therapy 3 for multiple myeloma: Prognostic implications of cumulative dosing and premature discontinuation of VTD maintenance components, bortezomib, thalidomide, and dexamethasone, relevant to all phases of therapy. American Society of Hematology.
Style de citation Chicagovan Rhee, Frits, et al. Total Therapy 3 for Multiple Myeloma: Prognostic Implications of Cumulative Dosing and Premature Discontinuation of VTD Maintenance Components, Bortezomib, Thalidomide, and Dexamethasone, Relevant to All Phases of Therapy. American Society of Hematology, 2010.
Style de citation MLAvan Rhee, Frits, et al. Total Therapy 3 for Multiple Myeloma: Prognostic Implications of Cumulative Dosing and Premature Discontinuation of VTD Maintenance Components, Bortezomib, Thalidomide, and Dexamethasone, Relevant to All Phases of Therapy. American Society of Hematology, 2010.